Cochrane · systematic review · CD004795
Fluoroquinolones for treating tuberculosis (presumed drug‐sensitive)
Ziganshina, LE, Titarenko, AF, Davies, GR · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
14
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 7 · 33.3%Very low 10 · 47.6%Low 4 · 19%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Fluoroquinolone plus standard regimen compared to standard regimen alone for presumed drug‐sensitive TB
Population: Patients with presumed drug‐sensitive TB
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment failure Fluoroquinolone plus standard regimen vs standard regimen alone | no estimate extracted | 0 studies · 0 participants | Ungraded |
Relapse Fluoroquinolone plus standard regimen vs standard regimen alone | no estimate extracted | 0 studies · 0 participants | Ungraded |
Death from any cause Fluoroquinolone plus standard regimen vs standard regimen alone | RR 0.27 [0.03, 2.47] | 1 study · 174 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
TB‐related death Fluoroquinolone plus standard regimen vs standard regimen alone | RR 0.8 [0.05, 12.4] | 1 study · 174 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Sputum culture conversion at 8 weeks Fluoroquinolone plus standard regimen vs standard regimen alone | RR 0.98 [0.91, 1.07] | 1 study · 174 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events Fluoroquinolone plus standard regimen vs standard regimen alone | RR 0.85 [0.4, 1.78] | 1 study · 174 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
One or more adverse event Fluoroquinolone plus standard regimen vs standard regimen alone | RR 1 [0.52, 1.92] | 1 study · 174 participants | Very low Downgraded: risk of bias, indirectness |
Fluoroquinolone substitution for ethambutol in a standard six month regimen compared to standard regimen for presumed drug‐sensitive TB
Population: Patients with presumed drug‐sensitive TB
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment failure Fluoroquinolone substitution for ethambutol in a standard six month regimen vs standard regimen | no estimate extracted | 0 studies · 0 participants | Ungraded |
Relapse Fluoroquinolone substitution for ethambutol in a standard six month regimen vs standard regimen | RR 0.71 [0.17, 3.06] | 1 study · 170 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Death from any cause Fluoroquinolone substitution for ethambutol in a standard six month regimen vs standard regimen | RR 0.52 [0.21, 1.32] | 3 studies · 723 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
TB‐related death Fluoroquinolone substitution for ethambutol in a standard six month regimen vs standard regimen | RR 0.33 [0.01, 8.07] | 1 study · 170 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Sputum culture conversion at 8 weeks Fluoroquinolone substitution for ethambutol in a standard six month regimen vs standard regimen | RR 1.07 [0.97, 1.19] | 3 studies · 723 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Serious adverse events Fluoroquinolone substitution for ethambutol in a standard six month regimen vs standard regimen | RR 0.93 [0.53, 1.62] | 3 studies · 723 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
One or more adverse events Fluoroquinolone substitution for ethambutol in a standard six month regimen vs standard regimen | no estimate extracted | 0 studies · 0 participants | Ungraded |
Fluoroquinolone substitution for isoniazid in a standard six month regimen compared to standard regimen for presumed drug‐sensitive TB
Population: Patients with presumed drug‐sensitive TB
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment failure Fluoroquinolone substitution for isoniazid in a standard six month regimen vs standard regimen | no estimate extracted | 0 studies · 0 participants | Ungraded |
Relapse Fluoroquinolone substitution for isoniazid in a standard six month regimen vs standard regimen | no estimate extracted | 0 studies · 0 participants | Ungraded |
Death from any cause Fluoroquinolone substitution for isoniazid in a standard six month regimen vs standard regimen | RR 0.75 [0.17, 3.3] | 1 study · 433 participants | Low Downgraded: risk of bias, imprecision |
TB‐related death Fluoroquinolone substitution for isoniazid in a standard six month regimen vs standard regimen | RR 2 [0.18, 21.84] | 1 study · 433 participants | Low Downgraded: risk of bias, imprecision |
Sputum culture conversion at 8 weeks Fluoroquinolone substitution for isoniazid in a standard six month regimen vs standard regimen | RR 1.1 [0.91, 1.33] | 1 study · 433 participants | Low Downgraded: risk of bias, imprecision |
Serious adverse events Fluoroquinolone substitution for isoniazid in a standard six month regimen vs standard regimen | RR 1.1 [0.43, 2.8] | 1 study · 433 participants | Low Downgraded: risk of bias, imprecision |
One or more adverse event Fluoroquinolone substitution for isoniazid in a standard six month regimen vs standard regimen | no estimate extracted | 0 studies · 0 participants | Ungraded |